FX.co ★ Guardant Health Q4 Prel. Revenue Rises 29%

Guardant Health, Inc. (GH), a company specializing in precision oncology, reported preliminary fourth-quarter revenue of $200 million, marking a 29% increase from the same period last year. The projected average revenue from 20 analysts was $188.92 million, with their estimates generally excluding extraordinary items. For the entire year, the company's preliminary revenue reached $737 million, reflecting a 31% growth. This figure surpasses the consensus estimate, which was $723.85 million.